“Our work is guided by a simple belief: the human body is capable of restoring itself when given the right signals. Our responsibility is to understand those signals and engineer them with precision.”

— Mohammed Ali Akbary, Founder

Maak Biotech operates through a global network of specialized scientific partners, managing research and development externally while establishing its strategic headquarters in Oman. From this base, the company coordinates regulatory development, translational research, and long-term innovation in peptide science. A central focus of our current work is the refinement and advancement of Peptide Sequence MK-1, a next-generation therapeutic candidate under investigation for potential applications in central nervous system (CNS) disorders, including spinal cord injury, stroke, multiple sclerosis, and Alzheimer’s disease. Preclinical studies in rodent models are ongoing as part of our structured scientific evaluation pathway.

Our vision is to establish a world-class Research and Regenerative Medicine Center in Muscat, positioning the Sultanate of Oman as a leading hub for synthetic peptide research and advanced neuroregeneration. Our mission is to contribute to Oman’s scientific and pharmaceutical ecosystem through high-quality, ethically aligned research capable of producing clinically meaningful breakthroughs. MK-1 is designed to support neural repair and functional recovery by modulating pathways associated with CSPG inhibition, axonal regeneration, remyelination, and synaptic plasticity, aligning with known mechanisms of ISP and LMWP peptide families.

The Regenerative Medicine Center under development will integrate three core pillars: regenerative and cellular therapies, peptide-based CNS repair, and rehabilitation-driven functional recovery. Our stem cell program focuses on mesenchymal stem cell isolation, controlled expansion, exosome and secretome formulation, and therapeutic programming, all conducted in adherence with Ministry of Health regulatory frameworks. To ensure biological repair is matched with neuromuscular recovery, Maak Biotech is partnering with Cyberdyne Japan to implement HAL robotic-assisted rehabilitation within the same clinical environment.

Our global partnership and licensing framework allows us to collaborate with leading research organizations and secure exclusive access to validated regenerative technologies for development and implementation within Oman. Together, these elements form a cohesive ecosystem dedicated to restoring human function through precision-engineered biological repair.

Maak Biotech & Research LLC
CR: 1595556 –S–OF–AL SEEB
Postal Code: 111 P.O box. No: 113
Muscat, Sultanate of Oman
Research | Peptide Development | Regenerative Medicine
Email: info@maakbiotech.com